By June 30, around 110 Hong Kong-listed biological medicine firms had unveiled their interim performance results. Data reveals that nearly 70 of these companies witnessed year-on-year revenue growth, with almost 10 firms boasting growth rates surpassing 100%. Moreover, approximately 80 companies reported positive net profits attributable to the parent company, with close to 40 achieving year-on-year growth, around 10 turning losses into gains, and nearly 30 seeing a year-on-year reduction in losses. As of September 3, the Hang Seng Innovative Drug Index had recorded a year-to-date surge of 117.55%, a clear indicator of a significant uptick in investor confidence within Hong Kong's biological medicine sector. Guoyuan Securities highlights that China's innovative drugs are now entering a phase of tangible results, marked by frequent R&D advancements, and predicts a continued improvement in the sector's performance during the latter half of the year.